

Date of Report: 16/07/2024

FOI - 418 - Treatment for Myelofibrosis

Questions	Notes/Comments	Response		
		Diagnosis	Number of Patients	Number of Admissions
<p><b>Q1. Please provide the total number of patients treated in the last 6 months for:</b></p> <ul style="list-style-type: none"> <li>• Polycythaemia Vera (ICD10 code D45)</li> <li>• Myelofibrosis (ICD10 code D47.4)</li> <li>• Myelofibrosis (ICD10 code D47.4) patients aged 65 and older</li> </ul>	<p>Provided in the 'Number of Patients' column are the number of patients who were discharged from an inpatient ward in MKUH between the <b>1st December 2023 and 31st May 2024</b>, with a diagnosis of <b>Polycythaemia Vera: ICD10 code of 'D45'</b> assigned to their admission in any order.</p> <p>Number of admissions column provides the number of times an inpatient was diagnosed and discharged from MKUH between <b>1st December 2023 and 31st May 2024</b>.</p>	Polycythaemia Vera	35	58
	<p>Provided in the 'Number of Patients' column are the number of patients who were discharged from an inpatient ward in MKUH between the <b>1st December 2023 and 31st May 2024</b>, with a diagnosis of <b>Myelofibrosis: ICD10 code of 'D47.4'</b> assigned to their admission in any order.</p> <p>Number of admissions column provides the number of times an inpatient was diagnosed and discharged from MKUH between <b>1st December 2023 and 31st May 2024</b>.</p>	Myelofibrosis	8	58
	<p>Provided in the 'Number of Patients' column are the number of patients, aged 65 and over, who were discharged from an inpatient ward in MKUH between the <b>1st December 2023 and 31st May 2024</b>, with a diagnosis of <b>Myelofibrosis: ICD10 code of 'D47.4'</b> assigned to their admission in any order.</p> <p>Number of admissions column provides the number of times an inpatient was diagnosed and discharged from MKUH between <b>1st December 2023 and 31st May 2024</b>.</p>	Myelofibrosis	7	51
<p><b>Q2. How many patients were treated in the past 6 months (for any disease) with:</b></p> <ul style="list-style-type: none"> <li>• Ruxolitinib</li> <li>• Fedratinib</li> <li>• Momelotinib</li> </ul>	<p>Provided are all patients treated between <b>1st December 2023 and 31st May 2024</b> with:</p> <ul style="list-style-type: none"> <li>• Ruxolitinib</li> <li>• Fedratinib</li> <li>• Momelotinib</li> </ul> <p><i>This data to be provided by Pharmacy.</i></p>		<ul style="list-style-type: none"> <li>• Ruxolitinib:</li> <li>• Fedratinib:</li> <li>• Momelotinib:</li> </ul>	
<p><b>Q3. How many patients were treated in the past 6 months for Myelofibrosis (ICD10 code D47.4) with:</b></p> <ul style="list-style-type: none"> <li>• Ruxolitinib</li> <li>• Fedratinib</li> <li>• Momelotinib</li> </ul>	<p>Provided are all patients treated in the past 6 months for Myelofibrosis: ICD10 code 'D47.4' between <b>1st December 2023 and 31st May 2024</b>.</p> <p><i>This data to be provided by Pharmacy.</i></p>		<ul style="list-style-type: none"> <li>• Ruxolitinib:</li> <li>• Fedratinib:</li> <li>• Momelotinib:</li> </ul>	
<p><b>Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?</b></p>	<p>Provided in the 'Number of Patients' column are the number of inpatients who were discharged from MKUH between the <b>1st May 2021 and the 31st May 2024</b>, with a diagnosis of Myelofibrosis: ICD10 code of 'D47.4', assigned to their admission in any order.</p> <p>Number of diagnosis provides the number of times an inpatient was diagnosed and discharged from an inpatient ward in MKUH between <b>1st May 2021 and 31st May 2024</b>.</p> <ul style="list-style-type: none"> <li>• Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?</li> <li>• Of these patients, how many were treated in the past 6 months with Interferon therapy?</li> <li>• Of these patients, how many have received no active treatment in the past 6 months?</li> </ul> <p><i>This data to be provided by Pharmacy.</i></p>	Number of Patients		Number of Diagnosis
<p><b>Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.</b></p>	<p><i>This is to be answered by the Pharmacy team.</i></p>			